Volition (linguistics)

Volition Presents at the 5th Annual Congress of the International Liquid Biopsy Society

Retrieved on: 
Friday, November 17, 2023
Liquid biopsy, Volition, NYSE, DNA, Introduction to genetics, Nucleic acid thermodynamics, Neoplasm, Plasma, CTCF, ESMO, Leukemia, PCR, Volition (linguistics), Blood, University, Cancer, Congress, Nucleoprotein, Hereditary nonpolyposis colorectal cancer, University of Lyon, Medical imaging, Vaccine, Biochemistry, Toxicology

HENDERSON, Nev, Nov. 17, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is presenting at the 5th Annual Congress of Liquid Biopsy being held in Madrid, Spain.

Key Points: 
  • HENDERSON, Nev, Nov. 17, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is presenting at the 5th Annual Congress of Liquid Biopsy being held in Madrid, Spain.
  • This data has generated significant interest from large diagnostic and liquid biopsy companies alike.
  • We are delighted to be presenting at the International Liquid Biopsy Society's Congress and furthering these discussions."
  • Volition has developed a novel method for liquid biopsy involving the first reported physical isolation of a class of tumor-derived ctDNA fragments from blood.

Volition to Reveal New Cancer Detection Method Insights at Upcoming Webinar

Retrieved on: 
Monday, October 2, 2023
Human, Q&A, Volition (linguistics), Health care, ESMO, Consultant (medicine), Cancer, Oncology, Hematology, Outline, Animal, European Society for Medical Oncology, NYSE, Nursing, Volition

Dr. Jake Micallef, Chief Scientific Officer at Volition, said:

Key Points: 
  • Dr. Jake Micallef, Chief Scientific Officer at Volition, said:
    "Our upcoming webinar is a timely opportunity to talk through exciting breakthrough data in our Capture pillar, regarding what we believe to be an entirely new method for the early detection of cancer.
  • We will provide stakeholders with deeper insights into the data we are presenting at ESMO 2023, and outline our next steps towards commercialization."
  • To register for Volition's data insights webinar click HERE.
  • Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals.

Volition Announces Clinical Research Study with Oncovet

Retrieved on: 
Monday, November 14, 2022
Securities Act of 1933, Lymphoma, Quality of life, Cancer, Technology, U.S. Securities and Exchange Commission, Radiation, Security (finance), Cardiology, Oncology, Dog, Animal, Forward-looking statement, Veterinarian, Histiocytic sarcoma, Cat, Name, Texas A&M University, Research, NYSE, Trial of the century, Securities Exchange Act of 1934, Internal medicine, Annual report, Patient, Failure, Volition (linguistics), COVID-19, Hemangiosarcoma, Human, Sepsis, Life, Professor, Science, Diagnosis, Disease, Neutrophil extracellular traps, Veterinary medicine, Medical device, Nucleosome, Volition

HENDERSON, Nev., Nov. 14, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced a clinical research study with Oncovet, a renowned veterinary referral clinic, specializing in medical and radiation oncology.

Key Points: 
  • HENDERSON, Nev., Nov. 14, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced a clinical research study with Oncovet, a renowned veterinary referral clinic, specializing in medical and radiation oncology.
  • The non-interventional study is being led by Dr. Jrme Benoit, Oncovet's Clinical Director, and will evaluate circulating nucleosomes of dogs and cats with cancer using Volition's Nu.Q Vet Cancer Test.
  • Dr. Jrme Benoit, Clinical Director at Oncovet, said: "Volition's Nu.Q Vet Cancer Test has already been shown to detect systemic cancers in dogs such as lymphoma and hemangiosarcoma.
  • Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, said: "We are delighted to collaborate with Dr. Benoit and his team on this research study.

Volition Announces U.S. Clinical Study for NETs

Retrieved on: 
Wednesday, August 10, 2022
U.S. Securities and Exchange Commission, Securities Act of 1933, Forward-looking statement, Failure, Securities Exchange Act of 1934, Security (finance), Research, Annual report, Life, Cancer, Quality of life, Patient, Neutrophil extracellular traps, Volition (linguistics), COVID-19, NETS, Sepsis, Science, Disease, Medical device, Volition, Nucleosome

Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life.

Key Points: 
  • Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life.
  • Volition is primarily focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
  • These forward-looking statements relate to, among other topics, Volition's expectations related to the potential uses, benefits and effectiveness of its Nu.Q NETs test.
  • Nucleosomics and Nu.Q and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries.

Volition Appoints DXOCRO to Spearhead U.S. FDA Strategy

Retrieved on: 
Monday, August 8, 2022
FDA, U.S. Securities and Exchange Commission, Drug Quality and Security Act, Quality, Laboratory, Forward-looking statement, NYSE, Failure, Technology, Securities Exchange Act of 1934, Cancer, Disease, LLC, Security (finance), Research, Annual report, Life, Marketing, Neutrophil extracellular traps, Volition (linguistics), Patient, Quality of life, COVID-19, State, Biotechnology, NETS, Sepsis, IVD, Securities Act of 1933, Science, Human, Animal, Development, Medical device, Volition, Nucleosome

They are an ideal partner for us as we develop our FDA strategy in the United States.

Key Points: 
  • They are an ideal partner for us as we develop our FDA strategy in the United States.
  • "DXOCRO will spearhead both our clinical product development and our regulatory program in the United States, and seek to establish clinical utility for our Nu.Q products.
  • Through the conduct of Volition's clinical validation studies, we hope to validate a broad range of potential Nu.Q products and support Volition's U.S. commercialization strategy."
  • Volition is primarily focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

VolitionRx Awarded $1.5 Million in Non-Dilutive Funding

Retrieved on: 
Wednesday, August 3, 2022
Failure, Human, Securities Act of 1933, Diagnosis, Security (finance), Annual report, COVID-19, Quality of life, Internet, Life, Wallonia, NYSE, Securities Exchange Act of 1934, Patient, U.S. Securities and Exchange Commission, Cancer, Volition (linguistics), Animal, Disease, Neutrophil extracellular traps, Technology, Research, Science, Forward-looking statement, Adoption, Sepsis, Pharmaceutical industry, Medical device, EU, Nucleosome, Volition

HENDERSON, Nev., Aug. 3, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced it has been awarded a further $1.5 million non-dilutive funding from Namur Invest Capital Risk in Belgium.

Key Points: 
  • HENDERSON, Nev., Aug. 3, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced it has been awarded a further $1.5 million non-dilutive funding from Namur Invest Capital Risk in Belgium.
  • "We will be working with centers of excellence worldwide providing leading clinicians and researchers with exclusive, early access to our Nu.Q product range.
  • Namur Invest's loan is the latest grant from agencies within the Walloon Region, amounting to more than $14 million in non-dilutive funding since 2016.
  • Nucleosomics and Nu.Q and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries.

Volition Signs Exclusive $28 million License and Supply Agreement with Heska Corporation to Distribute Nu.Q® Vet Cancer Screening Test at the Point of Care

Retrieved on: 
Tuesday, March 29, 2022
Human, Family, National Cancer Institute, NYSE, Caregiver, Volition (linguistics), Lymphoma, Research, Software, Technology, Sepsis, Securities Exchange Act of 1934, Securities Act of 1933, Dog, Solution, Annual report, Nu, Disease, Security (finance), Veterinarian, HSKA, PETS, Achievement, Health, Quality of life, Industry, U.S. Securities and Exchange Commission, Science, Animal, National, Morgan Stanley, Cancer, Life, NASDAQ, Investment, III, Forward-looking statement, Immunotherapy, Multimedia, Hemangiosarcoma, License, Name, National Food Security Act, 2013, Neutrophil extracellular traps, Patient, Texas A&M University, COVID-19, Professor, Pharmaceutical industry, Vaccine, Medical imaging, Medical device, Mobile phone, International, Volition, Nucleosome

In exchange for granting Heska these exclusive worldwide rights to sell the Nu.Q Vet Cancer Test, Volition will receive:

Key Points: 
  • In exchange for granting Heska these exclusive worldwide rights to sell the Nu.Q Vet Cancer Test, Volition will receive:
    up to $18 million based upon the achievement of near/mid-term milestones.
  • Volition's licensing agreement with Heska grants exclusive rights to commercialize the Nu.Q Vet Cancer Screening Test for canine cancer screening and monitoring at the point of care.
  • Volition's Nu.Q Vet Cancer Screening Test will operate on Heska's proprietary Element i+ Immunodiagnostic Analyzer, a point of care platform.
  • Heska's Nu.Q Vet Cancer Screening Test targetsone of the most critical challenges in pet healthcare.

Volition presents study data at ASCO GI 2022 on circulating nucleosomes for the detection of colorectal cancer and high-risk advanced adenomas

Retrieved on: 
Thursday, January 20, 2022
Securities Exchange Act of 1934, Forward-looking statement, Name, Nucleosome, Publication, Disease, U.S. Securities and Exchange Commission, Volition (linguistics), Cancer, Annual report, Security (finance), Securities Act of 1933, Medical device, Video game console, Volition

Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "can," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements.

Key Points: 
  • Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "can," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements.
  • For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations.
  • These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict.
  • All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.